← Leaderboards
Naiyer A Rizvi
Georgetown University
$2,808,393
Attributed
$4,186,574
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $733.6K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,186,574 · 6
By mechanism
R01$2,756,362 · 1
U01$1,187,442 · 1
R21$242,770 · 1
M01$0 · 3
Top collaborators
- Timothy An-Thy Chan7 shared
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchTumorImmunologicsCancer TherapyPathway InteractionsInsightMalignant NeoplasmsInnovationResistanceCell CycleMediatingResponseMutationMalignant Neoplasm Of LungDisease RemissionApoptoticCd8-Positive T-LymphocytesCharacteristicsAffinityClonalityClustered Regularly Interspaced Short Palindromic RepeatsCancer ModelCellsAutologous
Grant awards (18)
Elucidating genetics of response to immune checkpoint blockade in lung cancer$203,550
R01 · FY2021 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$558,644
R01 · FY2020 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$541,884
R01 · FY2019 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$558,644
R01 · FY2018 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$159,998
R01 · FY2018 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$573,644
R01 · FY2017 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$159,998
R01 · FY2017 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis$250,000
U01 · FY2008 · CA · contact PI
Phase I Clinical Trials of Novel Agents$464,385
U01 · FY2007 · CA · contact PI
Phase I Clinical Trials of Novel Agents$473,057
U01 · FY2006 · CA · contact PI
Correlation of EGFR Mutations and Response to Gefitinib$114,426
R21 · FY2006 · CA · contact PI
Correlation of EGFR Mutations and Response to Gefitinib$128,344
R21 · FY2005 · CA
PV701 Safety/Efficacy in Advanced/Recurrent Solid Tumors$0
M01 · FY2000 · RR
PV701 Safety/Efficacy in Advanced/Recurrent Solid Tumors$0
M01 · FY2000 · RR
Oral Dose Escalation of Tac-101 in Advanced Malignancies$0
M01 · FY2000 · RR
Oral Dose Escalation of Tac-101 in Advanced Malignancies$0
M01 · FY2000 · RR
Oral BMS-275291 Metalloproteinase Inhibitor in Cancer$0
M01 · FY2000 · RR
Oral BMS-275291 Metalloproteinase Inhibitor in Cancer$0
M01 · FY2000 · RR